Secondary analysis of a phase 3 RCT in 175 adults with symptomatic obstructive HCM: aficamten improved KCCQ-OSS more than metoprolol at 24 weeks (+7.8 points, 95% CI 3.3-12.3); SAQ summary gains were not significant (P=0.063).
Secondary analysisn = 175
Nassif et al. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy